Fiche centre
University of Chicago
Chicago — United States
Essais liés18clinical trials
VilleChicagolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06002945
Essais cliniques associés
18| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 4 | NCT04377555 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | COMPLETED |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| Anakinra | Épilepsie | Phase 3 | NCT07281027 | COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" | NOT_YET_RECRUITING |
| GBPDC: Gut-Brain in PD Consortium Master Protocol | Parkinson | À vérifier | NCT07567794 | GBPDC: Gut-Brain in PD Consortium Master Protocol | RECRUITING |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| ASP1570 | Cancer | Phase 1 | NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | TERMINATED |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | Myasthénie | À vérifier | NCT06002945 | EXPLORE-MG2 — Exploring Outcomes and Characteristics of Myasthenia Gravis 2 | COMPLETED |
| Mobile Health Management of Hypertension | Hypertension | Non applicable | NCT05856955 | Mobile Health Management of Hypertension | NOT_YET_RECRUITING |
| CRx-D — CommunityRx-Dementia | Alzheimer | Non applicable | NCT04146545 | CRx-D — CommunityRx-Dementia | COMPLETED |
| Hybrid argon plasma ablation (HAPC) | Cancer | Non applicable | NCT03621319 | BURN — Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique | TERMINATED |
| Histotripsie — HistoSonics Edison System | Cancer | À vérifier | NCT06486454 | Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | RECRUITING |
| Histotripsie — HistoSonics Edison System | Cancer | Non applicable | NCT04572633 | #HOPE4LIVER US — The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy | ACTIVE_NOT_RECRUITING |
| fenfluramine HCl | Épilepsie | À vérifier | NCT07555171 | EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment | ENROLLING_BY_INVITATION |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
| paclitaxel albumin-stabilized nanoparticle formulation | Cancer | Phase 2 | NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer | COMPLETED |